@article {38725,
	title = {First preclinical SPECT/CT imaging and biodistribution of [165Er]ErCl3 and [165Er]Er-PSMA-617},
	journal = {EJNMMI Radiopharm Chemistry},
	year = {2024},
	month = {12/2024},
	abstract = {<p>165Er (t1/2\&thinsp;=\&thinsp;10.4 h, Ex-ray\&thinsp;=\&thinsp;47.1\&nbsp;keV (59.4\%) and 54.3\&nbsp;keV (14.3\%)) is a promising radionuclide suitable for targeted Auger electron therapy of cancer. 165Er can be produced at a relatively low cost, high yield, and high purity using small medical cyclotrons. As a late lanthanide, 165Er is easy to label and can be used as a surrogate for other lanthanides or Ac in proof-of-concept studies. In this report, we explore the radiochemistry, in vitro, and in vivo behavior of [165Er]ErCl3 and [165Er]Er-PSMA-617 to showcase the application of this radionuclide. Particularly, we report the first phantom and preclinical SPECT imaging of this radionuclide leveraging its characteristic X-ray photon emissions.</p>},
	doi = {https://doi.org/10.1186/s41181-024-00312-9},
	author = {B. Saeedi and C. Rodr{\'\i}guez-Rodr{\'\i}guez and P. L. Esquinas and H. Merkens and F. B{\'e}nard and V. Radchenko and H. Yang}
}
